Anzeige
Mehr »
Dienstag, 23.06.2026 - Börsentäglich über 12.000 News
Schuldenfrei, 1,5 Mio. Unzen Gold und Produktion ab 2027: Vor dem Ausbruch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
422 Leser
Artikel bewerten:
(1)

CanaFarma Hemp Products Corp. Partners with APeT BV to Develop a Novel Hemp-Based Cannabinoid Capsule Delivery Mechanism

This news release is not for distribution or dissemination in the United States of America

VANCOUVER, BC / ACCESSWIRE / September 16, 2020 / CanaFarma Hemp Products Corp. (CSE:CNFA) (the "Corporation" or "CanaFarma") has partnered with APeT BV to develop novel Hemp-based cannabinoid, drug and nutritional supplement delivery methods via its FLOTEX-C patented technology. FLOTEX-C is a unique, patented, floating technology designed for safer and more effective delivery of active ingredients. FLOTEX-C is a Gastro-Retentive Drug Delivery System ("GRDDS"), whereby active ingredients are delivered in a time released manner via a capsule that "floats" within the stomach. FLOTEX-C has excellent floating capacity of at least 24 hours, whereby buoyancy increases in time thanks to the steady floating chamber.

The collaboration between the two companies will use the APeT BV FLOTEX-C technology to create novel approaches to infusing Hemp-based cannabinoids into a safer, self-repairing, better performing, gastro-retentive, controlled-release delivery platform for pharmaceuticals and nutraceuticals. Focus will be on anti-viral, immune boosting and anti-aging formulations.

Many patients are suffering from side effects from, or lack of efficacy of, their medication(s). Additionally, therapy compliance challenges such as too many pills spread over different hours of intake per day, can lead to skipping/forgetting to take the right amount of medication at the right time, or stopping the therapy all together. Canafarma and APeT's use of the FLOTEX-C technology will be designed with the objective of resolving many of these problems.

David Lonsdale, CEO of CanaFarma said, "We are delighted to be working with APeT on something so important to the industry, and our initial focus will be on anti-viral, immune boosting and anti-aging formulations to further develop the Company's consumer product brands."

About CanaFarma Hemp Products Corp.

CanaFarma Hemp Products Corp. is a full-service company operating in the hemp industry offering a full range of hemp-related products and services to the consumer wellness market. These products and services include growing top-quality hemp, providing hemp-processing services, and offering hemp-based products to consumers utilizing a well-established direct-to-consumer marketing approach.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties; and delay or failure to receive board, shareholder or regulatory approvals. Readers should not place undue reliance on forward-looking statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

FOR FURTHER INFORMATION, PLEASE CONTACT:

David Lonsdale
Chief Executive Officer
Phone: (214) 704-7942
Email: david@canafarmacorp.com

SOURCE: CanaFarma Hemp Products Corp.



View source version on accesswire.com:
https://www.accesswire.com/606140/CanaFarma-Hemp-Products-Corp-Partners-with-APeT-BV-to-Develop-a-Novel-Hemp-Based-Cannabinoid-Capsule-Delivery-Mechanism

© 2020 ACCESS Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.